Fibroblast–Myofibroblast Transition in Osteoarthritis Progression: Current Insights
International Journal of Molecular Sciences · 15.08.2025 · 26 (16) · 7881
DOI: 10.3390/ijms26167881 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.08.2025. Verfasst von Ruixin Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arthritis Clinical and Research Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. Hauptthemen laut MEDLINE: Osteoarthritis, Myofibroblasts, Fibroblasts. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis (OA) is a multifactorial joint disease traditionally characterized by cartilage degradation, while growing evidence underscores the critical role of synovial fibrosis in driving disease progression. The synovium exhibits pathological remodeling in OA, primarily due to the phenotypic transition of fibroblast-like synoviocytes (FLSs) into myofibroblasts. This fibroblast–myofibroblast transition (FMT) results in excessive deposition of extracellular matrix (ECM) and increased tissue stiffness and contractility, collectively contributing to chronic inflammation and fibrotic stiffening of the joint capsule. These fibrotic changes not only impair synovial function but also exacerbate cartilage degeneration, nociceptive sensitization, and joint dysfunction, thereby amplifying OA severity. Focusing on the frequently overlooked role of the FMT of synovial fibroblasts in OA, this review introduces the biological characteristics of FLSs and myofibroblasts and systematically examines the key molecular pathways implicated in OA-related FMT, including TGF-β, Wnt/β-catenin, YAP/TAZ, and inflammatory signaling cascades. It also discusses emerging therapeutic strategies targeting synovial fibrosis and FMT and considers their implications for the clinical management of OA. By highlighting recent advances and unresolved challenges, this review provides critical insights into the fibroblast–myofibroblast axis as a central contributor to OA progression and a promising therapeutic target for modifying disease trajectory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Arthritis Clinical and Research Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China.
- School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, NSW 2007, Australia.
ORCID-Profile: Zhen Yang, Jiao Jiao Li, Dan Xing
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Peng, R., Lin, Q., Yang, Z., Li, H., Li, J. J., & Xing, D. (2025). Fibroblast–Myofibroblast Transition in Osteoarthritis Progression: Current Insights. International Journal of Molecular Sciences, 26(16), 7881. https://doi.org/10.3390/ijms26167881
Vancouver
Peng R, Lin Q, Yang Z, Li H, Li JJ, Xing D. Fibroblast–Myofibroblast Transition in Osteoarthritis Progression: Current Insights. International Journal of Molecular Sciences. 2025;26(16):7881. doi:10.3390/ijms26167881
BibTeX
@article{Peng2025,
author = {Peng, Ruixin and Lin, Qiyuan and Yang, Zhen and Li, Hui and Li, Jiao Jiao and Xing, Dan},
title = {Fibroblast–Myofibroblast Transition in Osteoarthritis Progression: Current Insights},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7881},
doi = {10.3390/ijms26167881}
}
EUVIMED